Macrocyclic diaminopropanes as beta-secretase inhibitors

Details Macrocyclic diaminopropanes as beta-secretase inhibitors Macrocyclic diaminopropanes as beta-secretase inhibitors

2008-03-04

2008-03-04

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S456000

Reexamination Certificate

active

07338974

ABSTRACT:
There is provided a series of novel macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof,wherein R1, R2, R4, R5, n, L, Z, and as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

REFERENCES:
patent: WO 02/100856 (2002-12-01), None
patent: WO 03/072535 (2003-09-01), None
patent: WO 2004/013098 (2004-02-01), None
patent: WO 2004/062625 (2004-07-01), None
patent: WO 2005/018545 (2005-03-01), None
patent: WO 2005/049585 (2005-06-01), None
Hussain, I. et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase”,Mol. Cell. Neurosci, (1999) 14: 419-427.
Lin, X. et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein”, Proceedings of the National Academy of Sciences of the USA, (2000) 97: 1456-1460.
Ghosh, A.K., et al., “Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (β-secreatse)”,Bioorg. &Med. Chem. Letters, (2005) 15: 15-20.
Jennings, L.D., et al., “Acylguanidines as inhibitors of BACE-1: Variation of pyrrole ring substituents extending into the S1 and S3 pockets”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005.
Luo, Y., et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”,Nature Neuroscience(2001) 4: 231-232.
Roberds, S.L. et al., “BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics”,Human Molecular Genetics(2001) 10: 1317-1324.
Seiffert, D.; et al., “Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors”,J. Biol. Chem. (2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol. Rev. (2001) 81, 741-766.
Selkoe, D. J., “Biochemical Analyses of Alzheimer's Brain Lesions lead to the Identification of αβ and its Precursor”,Ann. Rev. Cell Biol. (1994) 10: 374-403.
Sinha, S., et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain”,Nature(London) (1999) 402: 537-540.
Solvibile, W.R. et al., “Thiophene acyl guanidines as BACE1 inhibitors”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005.
Stock, J.R., et al., “Acylguanidines as small molecule BACE1 inhibitors: Initial exploration of S1 and S2' pockets”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005.
Sukhdeo, M.N., et al., “Acylguanidines as small molecule BACE1 inhibitors: Optimization of the S1′ region”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005.
Thal, D. R., et al., “Two types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. and Exper. Neurology(2002) 61: 282-293.
Vassar, R., et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”,Science(1999) 286: 735-741.
Walsh, D. M., et al. “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem. (2001) 44, 2039-2060.
Yan, R. et al., “Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity”,Nature(1999) 402: 533-537.
Zhou, P., et al., “Acylguanidines as small molecule BACE1 inhibitors: Exploration of the S1 pocket”, Abstracts of Papers, 230thACS National Meeting, Washington, D.C., United States, Aug. 28-Sep. 1, 2005.

Affiliated with

Also associated with

Rating

Macrocyclic diaminopropanes as beta-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic diaminopropanes as beta-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic diaminopropanes as beta-secretase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2808607